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Abstract
Brain imaging and protein expression, from both cerebrospinal fluid and blood plasma, have been 
found to provide complementary information in predicting the clinical outcomes of Alzheimer’s 
disease (AD). But the underlying associations that contribute to such a complementary 
relationship have not been previously studied yet. In this work, we will perform an imaging 
proteomics association analysis to explore how they are related with each other. While traditional 
association models, such as Sparse Canonical Correlation Analysis (SCCA), can not guarantee the 
selection of only disease-relevant biomarkers and associations, we propose a novel discriminative 
SCCA (denoted as DSCCA) model with new penalty terms to account for the disease status 
information. Given brain imaging, proteomic and diagnostic data, the proposed model can perform 
a joint association and multi-class discrimination analysis, such that we can not only identify 
disease-relevant multimodal biomarkers, but also reveal strong associations between them. Based 
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on a real imaging proteomic data set, the empirical results show that DSCCA and traditional 
SCCA have comparable association performances. But in a further classification analysis, 
canonical variables of imaging and proteomic data obtained in DSCCA demonstrate much more 
discrimination power toward multiple pairs of diagnosis groups than those obtained in SCCA.
Keywords
Imaging genomics; Alzheimer’s disease; Proteomics; Canonical correlation analysis; Multi-class 
discrimination
1. Introduction
Alzheimer’s disease (AD) has been well known as one of the most common brain dementia, 
a major neurodegenerative disorder that has been characterized by gradual memory loss and 
brain behavior impairment. According to the latest report,1 more than 5 million Americans 
are living with Alzheimer’s and it has been officially listed as the 6th leading cause of death. 
Also, due to the significant decline of self-care capabilities during disease, it is not only the 
patients who suffer, but also the family members, friends, communities and the whole 
society considering the time-consuming daily care and high health care expenditures needed. 
In the past decade, deaths attributed to Alzheimer’s disease has increased 68 percent, while 
deaths attributed to the number one cause, heart disease, has decreased 16 percent. And all 
of these situations will continue to deteriorate as the population ages during the next several 
decades. To prevent such health care crisis, substantial efforts have been made to help cure, 
slow or stop the progression of the disease.
In the last few years, many efforts have been dedicated to explore whether the combination 
of multi-modal measures, e.g. brain atrophy measured by magnetic resonance imaging 
(MRI), hypometabolism measured by functional imaging and quantification of proteins, can 
better predict the clinical outcomes of AD, such as disease status and cognitive outcomes.19 
In many of these works, it has been found that brain imaging and protein expression, from 
both cerebrospinal fluid (CSF) and blood plasma, hold some complementary 
information.12,18 But how they are related with each other still remains elusive.
In this work, we will explore the relationships between brain imaging and protein expression 
using bi-multivariate association models. Sparse Canonical Correlation Analysis 
(SCCA)11,16 is a typical example that has been widely used for associative analysis in both 
real8,15 and simulated3 -omics data sets.2,11,17 But it can not guarantee the selection of 
disease-relevant biomarkers and therefore the associations generated in SCCA are not 
necessarily related to a specific disease either, unless the input features are already 
prefiltered disease-related biomarkers.5 On the other hand, most existing SCCA algorithms 
use the soft threshold strategy for solving the Lasso11,16 regularization terms, which assumes 
the independence structure of data features. Unfortunately, this independence assumption 
does not hold in neither imaging nor proteomics data, and will inevitably limit the capability 
of yielding optimal solutions.
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To overcome these limitations, we propose a novel discriminative SCCA (DSCCA) model, 
coupled with a new algorithm to eliminate the independence assumption, to explore the 
imaging and proteomic associations. Given imaging, proteomic and diagnostic data, the 
proposed model can perform a joint association and multi-class discrimination analysis. As 
such, we can not only identify disease-relevant multimodal biomarkers, but also reveal 
strong association between them. We perform an empirical comparison between the 
proposed DSCCA algorithm and a widely used SCCA implementation in the PMA software 
package (http://cran.r-project.org/web/packages/PMA/).16 The results show that DSCCA 
and SCCA have comparable association performances. But in a further classification 
analysis, canonical variables of imaging and proteomic data obtained in DSCCA 
demonstrate much more discrimination power toward diagnosis groups than those obtained 
in SCCA.
2. Discriminative SCCA (DSCCA)
Throughout this section, we denote vectors as boldface lowercase letters and matrices as 
boldface uppercase ones. For a given matrix M = (mij), we denote its i-th row and j-th 
column to mi and mj respectively. Let X = {x1, …, xn} ⊆ ℜp be the imaging data and Y = 
{y1, …, yn} ⊆ ℜq be the protein data, where n is the number of participants, p and q are the 
number of brain regions and proteins respectively.
Canonical correlation analysis (CCA) is a bi-multivariate method that explores the linear 
transformations of variables X and Y to achieve the maximal correlation between Xu and 
Yv, which can be formulated as:
(1)
where u and v are canonical loadings or weights, reflecting the significance of each feature 
in identified associations.
However, the power of CCA in biomedical applications is quite limited due to 1) its 
requirement on the relatively large number of observations n which is expected to exceed the 
combined dimension of X and Y, and 2) its nonsparse outputs u and v which make the 
ultimate pattern hard to interpret. To address this concerns, sparse CCA (SCCA) method was 
later proposed, where two penalty terms on both weight vectors P1(u) ≤ c1 and P2(v) ≤ c2 
were introduced to help generate sparse results.
A widely used SCCA implementation, PMA package,16 applied L1 norm penalty for both P1 
and P2. But without diagnosis information, its capability in identifying disease-relevant 
biomarkers is quite limited. Thus the ultimate association relationships are not necessarily 
related to a specific disease either. Another limitation of PMA is that it takes the soft 
threshold strategy in the solution, which requires the input data to have an linear 
independence design XTX = I and YTY = I (see Section 10 in14). Unfortunately, this 
independence assumption does not hold in both imaging and proteomics data (e.g., 
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correlated voxels in an ROI, correlated protein expressions), and will inevitably limit the 
capability of identifying meaningful imaging proteomics associations.
To overcome these limitations, we propose a novel discriminative SCCA (denoted as 
DSCCA) algorithm to not only take into account the diagnosis information but also 
eliminate the independence assumption. Inspired by the application of locality preserving 
projection (LPP) in linear discriminative analysis,10 we add two new constraints as P1 and 
P2 for multi-class discrimination.
(2)
Here, we construct two graphs Gw and Gb to account for the diagnosis groups, where each 
vertex indicates one subject (Fig. 1). In Gw, only subjects within the same diagnosis group 
have connections to each other. In other words, we build a complete graph for all the 
subjects belonging to the same diagnosis group. In Gb, only subjects from different 
diagnosis groups have connections. Lw and Lb are the Laplacian graphs of Gw and Gb 
respectively. While the traiditonal L1 norm helps ascertain the sparsity of selected imaging 
and protein biomarkers, the new penalty term ‖ · ‖D encourages the closeness between 
subjects within the same diagnosis groups and distance between subjects from different 
diagnosis groups after projection. α is a trade off parameter that help balance the within- and 
between-group constraints. Since canonical variables Xu and Yv have the exact same length, 
we use the same α for both penalties P1 and P2.
The final objective function of DSCCA can be written as follows:
(3)
Using Lagrange multipliers, Eq. (3) can be reformulated as follows:
(4)
Eq. (4) is known as a bi-convex problem, which can be easily solved using an alternating 
algorithm as discussed in.16 By fixing u and v respectively, we will have the following two 
minimization problems shown in Eq. (5) and (6).
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(5)
(6)
Both objective functions can be efficiently solved using the Nesterovs accelerated proximal 
gradient optimization algorithm.9 Algorithm 2.1 summarizes the optimization procedure. 
The convergence is based on the value changes of the objective function and we use 10−6 as 
stop criteria. Five-fold nested cross-validation was applied to automatically tune the 
parameters β1, β2, λ1 and λ2. According to,2 the learned pattern and performance are 
insensitive to γ1 and γ2 settings. Therefore in this paper we set both of them to 1 for 
simplicity. The optimization method used in steps 3 and 4 is similar to that proposed in.9
Algorithm 2.1
Discriminative SCCA (DSCCA)
Require:
X = {x1, …, xn}, Y = {y1, …, yn}, Lw ⊆ ℜn×n, Lb ⊆ ℜn×n
Ensure:
Canonical vectors u and v.
1: t = 1, Initialize ut ∈ ℜp×1, vt ∈ ℜq×1;
2: while not converge do
3:
  Solve Eq. (5) using Nesterov’s method and obtain u;
4:
  Solve Eq. (6) using Nesterov’s method and obtain v;
5:
  Scale u so that uTu = 1
6:
  Scale v so that vTv = 1
7:   t = t + 1.
8: end while
3. Results
3.1. Data and Experimental Setting
The MRI data, quantification of proteins in CSF and blood plasma were downloaded from 
the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database. The primary goal of 
ADNI has been to test whether serial MRI, PET, other biological markers, and clinical and 
neuropsychological assessment can be combined to measure the progression of mild 
cognitive impairment (MCI) and early AD. For up-to-date information, see 
adni.loni.usc.edu.
We totally extracted 246 subjects with all MRI, CSF and plasma proteomic data available. 
To balance the diagnostic groups, we randomly removed some mild cognitive impairment 
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(MCI) participants. Finally, 176 subjects (67 AD, 67 MCI and 42 healthy control (HC)), 
were included in this study (Table 1). For each baseline MRI scan, FreeSurfer (FS) V4 was 
employed to extract 73 cortical thickness measures and 26 volume measures, as well as to 
extract the intracranial volume (ICV). CSF and blood plasma samples were evaluated by 
Rules Based Medicine, Inc. (RBM) proteomic panel and 229 proteomic analytes survived 
the quality control process, with 83 from CSF and 146 from plasma. Using the regression 
weights from HC participants, all the MRI, CSF and blood plasma proteomic measures were 
pre-adjusted for the baseline age, gender, education, and handedness, with ICV as an 
additional covariate for MRI only.
3.2. Experimental Results
Both DSCCA and PMA were performed on the normalized FS and proteomic measures. To 
avoid the over-fitting problem, 5-fold nested cross-validation was applied, which also helped 
to optimally tune the parameters. Table 2 shows 5-fold cross-validation canonical correlation 
results. It is observed that proposed DSCCA and PMA have comparable performances in 
identifying imaging proteomic associations, whereas DSCCA is slightly better in 
performance stability.
Next, we examined the discriminative power of canonical variables Xu and Yv generated by 
DSCCA and PMA. Area under ROC curve (AUC) was calculated for each single canonical 
variable of five folds. Both imaging and proteomic canonical variables of PMA and imaging 
canonical variable of DSCCA were found to have little discrimination power in all HC vs 
MCI, HC vs AD and MCI vs AD cases. Proteomic canonical variable Yv of DSCCA has the 
best performance, with an averaged AUC around 0.7 for all three cases. Shown in Fig. 2 is 
an example plot of Xu against Yv in one fold. Dot colors represent different diagnostic 
groups. Compared to one single canonical variable, we observe that combination of two 
canonical variables generated in DSCCA demonstrated much more discrimination power 
than PMA. In Fig. 2(a) three diagnosis groups are all very well separated, whereas in Fig. 
2(b) subjects are mixing together.
To further validate our results, a follow up classification analysis was performed using both 
imaging and proteomic canonical variables as predictors. Canonical loadings learned in the 
training data set are applied to both training and test data to calculate the training and test 
canonical variables respectively. The LIBSVM toolbox was employed to implement the 
SVM using a linear kernel under default settings. Three pair-wise binary classification 
analyses were performed between HC vs MCI, HC vs AD, and MCI vs AD respectively. 
Shown in Table. 3 are the classification performance comparison between DSCCA and 
PMA. The results are very encouraging. Canonical variables of DSCCA significantly 
outperformed those of PMA in terms of the overall accuracy in almost all the cases. The 
resulting best prediction rates for HC vs AD (92.1%), HC vs MCI (75.3%) and MCI vs AD 
(70.3%) were competitive with prior multi-modal studies,6,19 especially considering that it is 
under default parameter settings.
All five-fold experiments generated similar sparse results in terms of selection of imaging 
and proteomic markers. Fig. 3 shows the imaging and proteomic markers commonly 
identified across all folds using DSCCA, where the color represents the weights of 
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corresponding brain regions. Top brain regions identified include entorhinal cortex, 
amygdala volume, hippocampal volume, etc. (Fig. 3(a)), which are all aligned with previous 
AD findings.12,19 In terms of proteomic markers, expression levels of 12 proteins from CSF 
and 19 proteins from blood plasma were found to be strongly associated with those brain 
regions. According to the STRING database (http://string-db.org/), these proteins are highly 
interconnected with each other, as shown in Fig. 3(b). Edges are colored based on the 
evidence of the connection, such as experimental interaction, co-expression or co-occurrence 
in the literature. The more edges two proteins have, the more confident their connection will 
be.
In particular, four proteins, apolipoprotein E (APOE), AXL receptor tyrosine kinase(AXL), 
interleukin 6 receptor (IL6R) and vascular endothelial growth factor (VEGF), were 
identified in both CSF and blood plasma. APOE is the top risk gene of AD. AXL is a 
member of the Tyro3-Axl-Mer (TAM) receptor tyrosine kinase subfamily, which has been 
previously reported to be involved in Amyloidogenic APP Processing and β-Amyloid 
Deposition in AD.20 For growth factor VEGF, both its variants and expression changes are 
found to be associated with AD.4,13 IL6R is less explored in terms of its relationship with 
dementia. But in a recent study it was reported to have significant associations with proteins 
involved in amyloid processing and inammation.7 These findings suggest the existence of 
certain connections between brain and blood biomarkers. Thus, more accessible fluid 
biomarkers from blood should have potential to provide extra insights of AD and guidance 
for future therapeutic intervention activities.
4. Discussion
We performed an integrative analysis of brain imaging and protein expression data to jointly 
identify AD related biomarkers and their associations using a new sparse learning model 
DSCCA. The overall association performance of DSCCA is better than SCCA. the 
combination of its two canonical variables are much more powerful in discriminating 
multiple diagnostic groups simultaneously. Using both imaging and proteomic canonical 
variables in DSCCA as predictors, we obtained very promising prediction performances: HC 
vs AD (92.1%), HC vs MCI (75.3%) and MCI vs AD (70.3%), which were competitive with 
prior multi-modal studies. Since the classification was done under default parameter settings 
and the sample size is very limited, we expect improved performances with more advanced 
parameter optimization strategies and/or larger sample sizes.
In real applications, many identified proteomic markers are found to be interconnected, but 
the underlying mechanisms still warrant further investigation. Replication in independent 
large samples will be important to confirm these findings. Further pathway enrichment 
analysis could be performed as a future direction to identify underlying biological pathways 
of relevant genes and proteins. Considering the ever increasing data volume and diversity in 
many complex diseases, another potential future topic is to investigate whether DSCCA can 
help identify valuable complementary information between new -omics features and further 
improve the classification performance.
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Fig. 1. 
Illustration of within- and between-group graphs Gw and Gb. Each circle indicates one 
subject and subjects from the same diagnosis group are colored the same.
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Fig. 2. 
Plot of canonical variables Xu and Yv. Left: DSCCA; Right: PMA; Red: AD; Green: MCI; 
Blue: HC; Solid: Training; Circle: Test.
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Fig. 3. 
Common imaging and proteomic markers across 5-fold cross-validation. (a): Mapping of 
imaging canonical loadings onto the brain; (b): Known interactions between identified 
protein biomarkers from STRING database.
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Table 1
Participant characteristics
HC MCI AD
Number 67 67 42
Gender(M/F) 38/29 45/22 22/20
Handedness(R/L) 64/3 64/3 38/4
Age(mean±std) 75.15±7.68 74.28±7.25 75.93±5.82
Education(mean±std) 15.12±3.01 15.96±2.92 15.88±2.77
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